NCT03875313: Study of CB-839 (Telaglenastat) in Combination With Talazoparib in Patients With Solid Tumors

Breast Cancer Type: HER2+, HR+ & HER2-negative, Triple Negative
Hormone Mutations: ER+, PR+
Other Mutations: 
Breast Cancer Tissue: 
Recruitment Status: Recruiting
Phase 1|Phase 2
Drug Category: Misc Inhibitor

Key Eligibility Criteria:

Gender: All
Age: 18 Years and older (Adult, Older Adult)
Location of Metastases: 
Additional Notes: Only TNBC patients will be eligible for part 2 (expansion phase)
Exclusions: Patients with active unstable, or untreated central nervous system metastasis- see trial for details; Patients with prior treatment of a PARP inhibitor

Comments are closed.

Up ↑